Description

3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-4-Oxo-7-[4-(4-Propoxybenzoyl)-1-Piperazinyl]- is a high-purity, advanced pharmaceutical intermediate of significant commercial importance. This compound is a key synthetic precursor in the development of novel fluoroquinolone antibiotics, offering critical structural complexity for targeted therapeutic action. It is essential for research and development laboratories, process chemists, and manufacturers in the global pharmaceutical and fine chemical industries seeking reliable, high-quality building blocks for active pharmaceutical ingredient (API) synthesis.

Application

• Pharmaceutical Intermediate: Primary building block for the synthesis of next-generation fluoroquinolone antibiotic candidates.
• Antimicrobial Research: Used in medicinal chemistry programs to develop new antibacterial agents with improved potency and spectrum of activity.
• Process Chemistry & Scale-Up: Serves as a critical intermediate in the optimization and commercial-scale manufacturing of APIs.
• Contract Manufacturing (CDMO): Supplied to contract development and manufacturing organizations for custom synthesis projects.
• Academic & Institutional Research: Utilized in university and institutional labs for studying structure-activity relationships (SAR) in antibiotic design.
• Reference Standard: Can be supplied as a high-purity standard for analytical method development and quality control in API production.

Basic Information

Item	Detail
Product Name	3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-4-Oxo-7-[4-(4-Propoxybenzoyl)-1-Piperazinyl]-
CAS No.	1054130-45-8
Molecular Formula	C27H28FN3O5
Molecular Weight	493.53 g/mol
Synonyms	1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-(4-propoxybenzoyl)piperazin-1-yl]quinoline-3-carboxylic acid; 7-[4-(4-Propoxybenzoyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; WCK 771 Intermediate; Advanced Fluoroquinolone Intermediate; Garenoxacin related compound intermediate
EINECS	Contact for details

Quality Control

Every batch of this pharmaceutical intermediate is produced under strict quality management systems and undergoes comprehensive analytical testing. We ensure compliance with ICH guidelines for impurities and utilize advanced techniques like HPLC, GC, and NMR for characterization. A detailed Certificate of Analysis (COA) is provided with each shipment, confirming identity, purity, and impurity profiles to meet your specific project requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (typically 15-25°C). The compound may be hygroscopic (moisture-sensitive); therefore, the container must be kept tightly sealed under inert atmosphere if specified.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤ 0.5% w/w
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.